1-4 of 4
Nicholas J. Donato, Ph.D
Close
Sort by
Journal Articles

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Nicholas J Donato, Ph.D., Hanshi Sun, Ph.D., Vaibhav Kapuria, Luke F Peterson, PhD, Geoffrey Bartholomeusz, Ph.D., William G. Bornmann, Ph.D., Moshe Talpaz, M.D.
Journal: Blood
Blood (2009) 114 (22): 3303.
https://doi.org/10.1182/blood.V114.22.3303.3303
Published: 2009
Journal Articles

Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in “Classic” and “Blastoid-Variant” Mantle Cell Lymphoma.

Lan V. Pham, PhD, Archito T. Tamayo, Linda C. Yoshimura, Waldeman Priebe, Ph.D, Nicholas J. Donato, Ph.D, Moshe Talpaz, MD, Richard J. Ford, MD, Ph.D
Journal: Blood
Blood (2006) 108 (11): 2512.
https://doi.org/10.1182/blood.V108.11.2512.2512
Published: 2006
Journal Articles

Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, Ph.D., William Bornmann, Ph.D., Ling Y. Kong, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 3423.
https://doi.org/10.1182/blood.V108.11.3423.3423
Published: 2006
Journal Articles

The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms.

Nicholas J. Donato, Ph.D., Ji Wu, M.D., Ling Y. Kong, Ph.D., M.D., Francis Lee, Ph.D., Moshe Talpaz, M.D.
Journal: Blood
Blood (2004) 104 (11): 1989.
https://doi.org/10.1182/blood.V104.11.1989.1989
Published: 2004